Our Spotlight (OTCBB- AMBS) News Today – up 100%+ congrats
SmallCapStockPlays Newsletter
Dear Members, Amarantus BioSciences Announces the Release of Research Report by OneMedPlace [1]CLICK HERE FOR QUOTE SUNNYVALE, Calif., Sept. 24, 2012 –/PRNewswire/ — Amarantus BioSciences, Inc.
(OTCBB: AMBS), a California-based development-stage biotechnology developing new treatments and diagnostics for Parkinson`s disease (PD) centered around its patented therapeutic protein MANF, today announced the release of a 2-page research report by OneMedPlace Research. The report can be found at[2]http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf.
The report states: “Treatment with MANF prior to inducing PD-like conditions in animals protected the subjects from the onset of neuron degeneration. Even more impressively, in animals where Parkinson`s was already present, treatment with MANF provided restorative benefits that included regaining motor function, as well as the maintenance and increase in function of the neurons that were still present. Cumulatively, these studies provide strong evidence that MANF has the potential to serve as a first-in-class curative treatment for degenerative neurological disorders that include PD. Amarantus is currently in the design and development stages to move MANF into clinical trials.” The report also states: “Amarantus owns the license for Power3 Medical Products` NuroPro Blood Test as it relates to Parkinson`s disease. NuroPro is a diagnostic platform for the early detection of neurodegenerative diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies.” About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson`s disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF“).
For further information please visit [3]www.amarantus.com.
Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus` PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus` new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus` new product candidates, including those identified under “Risk Factors” in Amarantus` most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Read more here:
http://www.sacbee.com/2012/09/24/4848994/amarantus-biosciences-announces.html#st orylink=cpy Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company`s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company`s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company`s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company`s filings with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. SmallCapStockPlays is a wholly-owned subsidiary of First Equity Group Inc. , any future email regarding a specific company will be the result of an advertising and promotional campaign for which First Equity Group Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research.
Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results.
Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Regards, First Equity Group Inc.
20283 State Road 7, Suite 300 Boca Raton FL 33498 561-807-6350 info@smallcapstockplays.com References 1. http://www.google.com/financeq=OTC%3AAMBS&ei=OpJgUJjrLcio0AGYdw 2. http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf 3. http://www.amarantus.com/
This message was sent to from:
first equity group inc | 20283 State Road 7, Suite 300 | Boca Raton, Fl 33498